Drug Profile


Alternative Names: OR 1384

Latest Information Update: 20 Oct 2003

Price : $50

At a glance

  • Originator Orion
  • Class Small molecules; Sulfhydryl compounds
  • Mechanism of Action Immunomodulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Crohn's disease; Inflammatory bowel diseases

Most Recent Events

  • 20 Oct 2003 Discontinued - Phase-I for Chronic obstructive pulmonary disease in Finland (Inhalation)
  • 20 Oct 2003 Discontinued - Phase-I for Asthma in Finland (Inhalation)
  • 20 Oct 2003 Discontinued - Phase-I for Inflammatory bowel disease in Finland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top